By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TWi Pharmaceuticals, Inc. 

4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.  Taipei  114 
Phone: 886-2-26573350 Fax: 886-2-26573391




Company News
TWi Pharmaceuticals, Inc. Receives Favorable Decision From The U.S. Court Of Appeals For The Federal Circuit Regarding TWi's Generic Version Of MEGACE ES 625mg/5ml 12/16/2015 6:23:43 AM
TWi Pharmaceuticals, Inc. Issues GDR And Raised NT$ 2.83 Billion 9/17/2015 6:45:04 AM
TWi Pharmaceuticals, Inc. President & CEO Ms. Tina Guilder Will Resign From Her Current Roles And Chairman Dr. Chih-Ming Chen Will Become Interim President & CEO, Leading The Company In Its Continued Efforts To Develop High-Entry-Barrier Generics For The U.S. Market 8/31/2015 6:59:55 AM
TWi Pharmaceuticals, Inc. Announces 2Q 2015 Financial Results And EPS For 2Q Of NT$0.69 8/14/2015 6:58:56 AM
TWi Pharmaceuticals, Inc. Release: Twi Biotechnology Receives Notice Of Patent Allowance For Its Lead Drug Candidate AC-201 For The Indication Of Type II Diabetes In Europe And Russia 8/3/2015 6:46:30 AM
TWi Pharmaceuticals, Inc. Launches Generic MEGACE ES After Favorable Decision In Patent Suit 7/29/2015 11:29:18 AM
TWi Pharmaceuticals, Inc. Receives U.S. FDA Final Approval On Generic Guanfacine HCl ER Tablet 6/3/2015 9:11:01 AM
TWi Pharmaceuticals, Inc. Announced The Promotion Of R&D EVP Jianbo Xie As COO 5/14/2015 6:40:58 AM
TWi Pharmaceuticals, Inc. Announces Settlement With Takeda (TKPYY) On Dexilant(R) Litigation 4/27/2015 7:01:20 AM
TWi Pharmaceuticals, Inc. USA Announces The Receipt Of State Sales Licenses From All 50 States In The U.S. 4/17/2015 7:36:06 AM